Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Starpharma and Monash University collaboration

Abstract:
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) and the Monash Institute of Pharmaceutical Sciences (MIPS) have been awarded an Australian Research Council funding grant for the purpose of advancing a new drug delivery method that may benefit thousands of patients with particular types of cancer, HIV and lymphatic conditions world-wide.

Starpharma and Monash University collaboration

Melbourne, Australia | Posted on June 29th, 2010

Innovation Minister Kim Carr awarded Starpharma and MIPS $420,000 as part of the ARC's Linkage Projects scheme aimed at encouraging Australian institutions to undertake innovative and cutting edge research projects in collaboration with industry and other partners.

"This funding will assist in advancing our collaboration with researchers from Monash University over the next three years, to further understand the full potential of Starpharma's proprietary dendrimers in improving drug delivery," said Dr Jackie Fairley, CEO of Starpharma. "This research has the potential to significantly improve the treatment of diseases, including metastatic cancer, lymphoma, HIV and metastitial tuberculosis."

Professor Chris Porter, lead researcher and Associate Dean of Research at MIPS, said the technology has particular implications for the treatment of diseases which are spread via the lymphatics and lymph nodes.

"Our work so far suggests that careful design of the size and surface characteristics of certain dendrimers provides an opportunity to boost delivery to the lymphatic system, signalling the potential to significantly improve patient treatment," Professor Porter explained. "This Linkage grant provides an excellent opportunity to explore these issues in detail and to advance the development of targeted therapeutics".

The ability to target therapeutics in this way has the potential to enhance efficacy and reduce side effects and toxicity of treatments. The approach also prolongs the lifetime of the drug in question by slowing the process of drug breakdown. This maximises the opportunities for the drug to reach the relevant sites in the body before being cleared by the body's natural mechanisms.

The delivery method relies on dendrimer technology. Dendrimers are precisely defined biofriendly molecules 3-10 nanometres in diameter. They are approximately spherical in shape with a surface which has many different sites to which drugs and other functional groups may be attached, allowing optimisation of how the drug interacts with the body.

Forward Looking Statements
This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "est mated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

####

About Starpharma
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the development of dendrimer technology for pharmaceutical, life-science and other applications. SPL has two operating companies, Starpharma Pty Ltd in Melbourne, Australia and DNT, Inc in the USA. Products based on SPL’s dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents through licence arrangements with partners including Siemens and Merck KgA.

The Company’s lead pharmaceutical development product is VivaGel® (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes. In September 2008 Starpharma signed a full licence agreement with SSL International plc (LSE:SSL) to develop a VivaGel® coated condom. SSL manufactures and sells Durex® condoms, the market-leading condom brand worldwide.

Starpharma also has agreements in place with Lilly, Elanco, Stiefel Laboratories (a GSK Company), and Unilever as well as many research collaborations with some of the world’s leading organisations.

Dendrimer: A type of precisely-defined, branched nanoparticle. Dendrimers have applications in the medical, electronics, chemicals and materials industries.

American Depositary Receipts (ADRs): Starpharma’s ADRs trade under the code SPHRY (CUSIP number 855563102). Each Starpharma ADR is equivalent to 10 ordinary shares of Starpharma as traded on the Australian Securities Exchange (ASX). The Bank of New York Mellon is the depositary bank. Starpharma’s ADRs are listed on International OTCQX (www.otcqx.com), a premium market tier in the U.S. for international exchange-listed companies, operated by Pink OTC Markets, Inc.

For more information, please click here

Contacts:
Media
Buchan Consulting
Rebecca Wilson
Tel: +61 3 9866 4722
Mob: +61 417 382 391


Ellie Papathanasiou
Tel: +61 2 9237 2800
Mob: +61 405 342 490


Starpharma
Dr Jackie Fairley
Chief Executive Officer
+61 3 8532 2704

Ben Rogers
Company Secretary
+61 3 8532 2702

Copyright © Starpharma

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Rutgers, NIST physicists report technology with potential for sub-micron optical switches March 31st, 2015

Prototype 'nanoneedles' generate new blood vessels in mice: Scientists have developed tiny 'nanoneedles' that have successfully prompted parts of the body to generate new blood vessels, in a trial in mice March 31st, 2015

Super sensitive measurement of magnetic fields March 31st, 2015

Nanomedicine pioneer Mauro Ferrari at ETH Zurich March 31st, 2015

Possible Futures

Nanotechnology in Medical Devices Market is expected to reach $8.5 Billion by 2019 March 25th, 2015

Nanotechnology Enabled Drug Delivery to Influence Future Diagnosis and Treatments of Diseases March 21st, 2015

Nanocomposites Market Growth, Industry Outlook To 2020 by Grand View Research, Inc. March 21st, 2015

Nanotechnology Drug Delivery Market in the US 2012-2016 : Latest Report Available by Radiant Insights, Inc March 16th, 2015

Academic/Education

SUNY Poly CNSE and Title Sponsor SEFCU Name Capital Region Teams Advancing to the Final Round of the 2015 New York Business Plan Competition March 30th, 2015

LAMDAMAP 2015 hosted by the University March 26th, 2015

SUNY Poly & M+W Make Major Announcement: Major Expansion To Include M+W Owned Gehrlicher Solar America Corporation That Will Create up to 400 Jobs to Develop Solar Power Plants at SUNY Poly Sites Across New York State March 26th, 2015

SUNY POLY CNSE to Host First Ever Northeast Semi Supply Conference (NESCO) Conference Will Connect New and Emerging Innovators in the Northeastern US and Canada with Industry Leaders and Strategic Investors to Discuss Future Growth Opportunities in NYS March 25th, 2015

Nanomedicine

Nanion Technologies Appoints James Costantin as Director of Customer Relations: Nanion is pleased to announce the appointment of Dr. James Costantin as Director of Customer Relations at Nanion Technologies Inc. March 31st, 2015

Nanomedicine shines light on combined force of nanomedicine and regenerative medicine March 31st, 2015

Prototype 'nanoneedles' generate new blood vessels in mice: Scientists have developed tiny 'nanoneedles' that have successfully prompted parts of the body to generate new blood vessels, in a trial in mice March 31st, 2015

Nanomedicine pioneer Mauro Ferrari at ETH Zurich March 31st, 2015

Announcements

Rutgers, NIST physicists report technology with potential for sub-micron optical switches March 31st, 2015

Prototype 'nanoneedles' generate new blood vessels in mice: Scientists have developed tiny 'nanoneedles' that have successfully prompted parts of the body to generate new blood vessels, in a trial in mice March 31st, 2015

Super sensitive measurement of magnetic fields March 31st, 2015

Nanomedicine pioneer Mauro Ferrari at ETH Zurich March 31st, 2015

Grants/Awards/Scholarships/Gifts/Contests/Honors/Records

Nanomedicine pioneer Mauro Ferrari at ETH Zurich March 31st, 2015

SUNY Poly CNSE and Title Sponsor SEFCU Name Capital Region Teams Advancing to the Final Round of the 2015 New York Business Plan Competition March 30th, 2015

Princess Margaret scientists convert microbubbles to nanoparticles: Harnessing light to advance tumor imaging, provide platform for targeted treatment March 30th, 2015

FEI Technology Award of the German Neuroscience Society Goes to Benjamin Judkewitz of the University of Berlin: Bi-annual award honors excellence in brain research during the German Neuroscience Society’s Annual Meeting, held 18-21 March 2015 March 26th, 2015

Nanobiotechnology

From tobacco to cyberwood March 31st, 2015

Wrapping carbon nanotubes in polymers enhances their performance: Scientists at Japan's Kyushu University say polymer-wrapped carbon nanotubes hold much promise in biotechnology and energy applications March 30th, 2015

'Atomic chicken-wire' is key to faster DNA sequencing March 30th, 2015

Designer's toolkit for dynamic DNA nanomachines: Arm-waving nanorobot signals new flexibility in DNA origami March 27th, 2015

Research partnerships

Rutgers, NIST physicists report technology with potential for sub-micron optical switches March 31st, 2015

Prototype 'nanoneedles' generate new blood vessels in mice: Scientists have developed tiny 'nanoneedles' that have successfully prompted parts of the body to generate new blood vessels, in a trial in mice March 31st, 2015

'Atomic chicken-wire' is key to faster DNA sequencing March 30th, 2015

SUNY Poly & M+W Make Major Announcement: Major Expansion To Include M+W Owned Gehrlicher Solar America Corporation That Will Create up to 400 Jobs to Develop Solar Power Plants at SUNY Poly Sites Across New York State March 26th, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2015 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE